Qian Hao, Ying Guohuan, Xu Haifeng, Wang Shangyu, Wu Bing, Wang Xin, Qi Hongdan, He Mingying, Ud Din M Jalal, Huang Tingting, Wu Yimei, Zhang Gang
Department of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China.
Med Int (Lond). 2024 Jul 19;4(6):57. doi: 10.3892/mi.2024.181. eCollection 2024 Nov-Dec.
Glucose transporter type 1 deficiency syndrome (GLUT1-DS) is a rare metabolic encephalopathy with a wide variety of clinical phenotypes. In the present study, 15 patients diagnosed with GLUT1-DS were selected, all of whom had obvious clinical manifestations and complete genetic testing. Their clinical data and genetic reports were collated. All patients were provided with a ketogenic diet (KD) and an improvement in their symptoms was observed during a follow-up period of up to 1 year. The results revealed that the 15 cases had clinical symptoms, such as convulsions or dyskinesia. Although none had a cerebrospinal fluid/glucose ratio <0.4, the genetic report revealed that all had the solute carrier family 2 member 1 gene variant, and their clinical symptoms basically improved following the use of the KD. GLUT1-DS is a genetic metabolic disease that causes a series of neurological symptoms due to glucose metabolism disorders in the brain. Low glucose levels in cerebrospinal fluid and genetic testing are key diagnostic criteria, and the KD is a highly effective treatment option. By summarizing and analyzing patients with GLUT1-DS, summarizing clinical characteristics and expanding their gene profile, the findings of the present study may be of clinical significance for the early recognition and diagnosis of the disease, so as to conduct early treatment and shorten the duration of brain energy deficiency. This is of utmost importance for improving the prognosis and quality of life of affected children.
1型葡萄糖转运体缺乏综合征(GLUT1-DS)是一种罕见的代谢性脑病,具有多种临床表型。在本研究中,选取了15例诊断为GLUT1-DS的患者,所有患者均有明显的临床表现且基因检测完整。整理了他们的临床资料和基因报告。所有患者均接受生酮饮食(KD),在长达1年的随访期内观察到症状有所改善。结果显示,这15例患者有惊厥或运动障碍等临床症状。虽然无一例脑脊液/葡萄糖比值<0.4,但基因报告显示所有患者均有溶质载体家族2成员1基因变异,使用KD后其临床症状基本改善。GLUT1-DS是一种遗传性代谢疾病,由于大脑葡萄糖代谢紊乱导致一系列神经症状。脑脊液葡萄糖水平降低和基因检测是关键诊断标准,KD是一种高效的治疗选择。通过总结分析GLUT1-DS患者,总结临床特征并扩展其基因谱,本研究结果可能对该疾病的早期识别和诊断具有临床意义,从而进行早期治疗并缩短脑能量缺乏的持续时间。这对于改善患病儿童的预后和生活质量至关重要。